BCL2 and diffuse large B-cell lymphoma: Importantly, we also demonstrate synergy between PI3K/mTOR and BCL-2 inhibition in chemo-resistant DLBCL lines over-expressing BCL-2, but show that this combination lacked toxicity in normal T lymphocytes.